Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 1100-1102

  Nanki, Toshihiro ^a   Onoue, Ikumi ^a   Nagasaka, Kenji ^b   Takayasu, Aiko ^a   Ebisawa, Masashi ^a   Hosoya, Tadashi ^a   Shirai, Toshizumi ^b   Sugihara, Takahiko ^c   Hirata, Shinya ^a   Kubota, Tetsuo ^a   Harigai, Masayoshi ^a   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Ome Municipal General Hospital   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; C REACTIVE PROTEIN; INTERLEUKIN 6 ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; CASE REPORT; CAUSE OF DEATH; CHEST INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EMPYEMA; EPITOPE MAPPING; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; SKIN ABSCESS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS INTERMEDIUS;

AUTOANTIBODIES; CYTOKINES; INFECTIONS;

AGED; AUTOANTIBODIES; C-REACTIVE PROTEIN; EMPYEMA, PLEURAL; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; MIDDLE AGED; STAPHYLOCOCCAL SKIN INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 84877610527     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202768     Document Type: Letter

References (9)

1. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. The Biochem J 1990;265:621-36. (Pubitemid 20053863)
2. Norrby A, Norgren M, Holm SE. Elevated levels of interleukin 6 in serum of patients with serious group A streptococcal infections. Infection 1992;20:369-70. (Pubitemid 23010001)
3. Soderquist B, Sundqvist KG, Vikerfors T. Kinetics of serum levels of interleukin-6 in Staphylococcus aureus septicemia. Scand J Infect Dis 1992;24:607-12.
4. Puel A, Picard C, Lorrot M, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 2008;180:647-54.
5. Galle P, Svenson M, Bendtzen K, et al. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 2004;34:3267-75. (Pubitemid 39549405)
6. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-219.
7. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 2012;51:852-7.
8. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51.
9. Boulanger MJ, Chow DC, Brevnova EE, et al. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003;300:2101-4. (Pubitemid 36760138)